Results from the PIONEER 6 trial suggest that oral semaglutide is safe for patients with type 2 diabetes at high cardiovascular (CV) risk. PIONEER researchers, including Mansoor Husain, MD, and John B. Buse, MD, PhD, reported that oral semaglutide, the first GLP-1 receptor agonist for oral administration, reduced CV death and all-cause mortality by nearly…

The results of two major outcome trials — CREDENCE and CARMELINA — targeting patients with type 2 diabetes and chronic kidney disease were presented on Tuesday, June 11, the final day of the 79th Scientific Sessions in San Francisco, CA. Meg Jardine, MD, PhD, discusses CREDENCE results and Darren K. McGuire, MD, MHSc, reports on…

In a head-to-head comparison of linagliptin, a DPP-4 inhibitor, and glimepiride, a sulfonylurea, researchers found no difference in risk for cardiovascular mortality or overall mortality in patients with type 2 diabetes, according to Julio Rosenstock, MD.

Dulaglutide, an injectable GLP-1 receptor agonist, can be considered for both primary and secondary cardiovascular prevention in middle-aged and older patients with type 2 diabetes and cardiovascular risk factors, according to results from the REWIND trial reported by Hertzel C. Gerstein, MD, MSc, FRCPC, and Matthew C. Riddle, MD.

Results from the DECLARE-TIMI 58 trial suggest that the SGLT2 inhibitor dapagliflozin not only reduces insulin resistance and reduces cardiovascular risk factors, but also prevents heart failure and progression of kidney disease in most diabetes patients, including those with normal heart and kidney function, with high safety, according to co-principal investigator Itamar Raz, MD.

Results from the RISE Clinical Trial showed no long-term improvement in beta-cell function from various diabetes treatments. Improvements seen during the 12-month treatment period had disappeared three months later, and A1C worsened in two of the treatment arms, according to Steven E. Kahn, MB, ChB.

Susanne M. Cabrera, MD, and three other researchers presented results from four recent and ongoing studies from the TrialNet network at the Scientific Sessions. TrialNet is a global consortium of researchers dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Results from the PREVIEW study, which compared the benefits of two diet and two weight management programs, showed comparable rates of delay toward type 2 diabetes development in patients with prediabetes who had initially lost weight on a low-calorie diet, according to Ian MacDonald, BSc, PhD.

The longest-running study of type 2 diabetes in young people, the TODAY2 Study, is winding down. Results to date show that youth-onset type 2 diabetes is more aggressive than adult-onset disease, according to Philip Zeitler, MD, PhD, who co-chaired a session at the 79th Scientific Sessions that provided the latest look at results from the…

Among vitamin D-sufficient adults at high risk for type 2 diabetes, vitamin D supplementation at a dose of 4000 IU per day did not significantly lower the risk of diabetes compared to placebo, according to the results of the D2d Study presented at the Scientific Sessions by Anastassios G. Pittas, MD, MS.